Using nanoparticles to deliver targeted therapies for glioblastoma treatment
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11041126
This study is exploring a new way to deliver treatments directly to glioblastoma, a tough brain tumor, using special tiny particles that can cross the protective barrier in the brain, with the hope of making existing therapies work better for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11041126 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel method to deliver targeted therapies for glioblastoma, a highly aggressive brain tumor. The approach involves using bi-compartmental nanoparticles designed to effectively cross the blood-brain barrier, which is a significant challenge in treating brain tumors. By targeting the STAT3 signaling pathway, which is crucial for tumor growth, the research aims to enhance the efficacy of existing treatments like small molecule inhibitors and chemotherapy drugs. Patients may benefit from improved treatment outcomes through this innovative delivery system.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing standard treatment protocols.
Not a fit: Patients with other types of brain tumors or those who are not eligible for glioblastoma treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using nanoparticle delivery systems for brain tumors, indicating that this approach could be a viable option.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAHANN, JOERG — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: LAHANN, JOERG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.